{"url_path":"/sec/tvtx/8-k/2026-05-21/item-9-01","section_key":"item-9-01","section_title":"Item 9.01 Financial Statements and Exhibits.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-05-21","source_url":"https://www.sec.gov/Archives/edgar/data/1438533/0001438533-26-000046-index.html","accession_number":"0001438533-26-000046","cik":"0001438533","ticker":"TVTX","issuer_name":"Travere Therapeutics, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1438533/0001438533-26-000046-index.html","primary_entity_key":"0001438533","primary_entity_name":"Travere Therapeutics, Inc."},"word_count":82,"has_tables":true,"body_markdown":"Item 9.01    Financial Statements and Exhibits.\n\n(d)    Exhibits\n\nExhibit No.Description\n\n99.1\n[Travere Therapeutics, Inc. 2018 Equity Incentive Plan, as amended.](ex991_8-kx20260519eip.htm)\n\n104Cover Page Interactive Data File (embedded within the Inline XBRL document).\n\nPursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.\n\n \n\n    TRAVERE THERAPEUTICS, INC.\n\n    \n\nDated: May 21, 2026   By:/s/ Elizabeth E. Reed\n\n      Name:Elizabeth E. Reed\n\nTitle:Chief Legal Officer, General Counsel & Secretary"}